Selective NaV1.6 Blockers for Seizure Control With Less Neurotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy and other sodium channel-related disorders, such as chronic pain and neuropathic pain, are inadequate, with many patients experiencing seizures despite optimal doses of antiepileptic drugs and suffering from medication-induced neurotoxicity and cognitive side effects.
Innovation Solution
Development of compounds that selectively target certain sodium channel isoforms, particularly NaV1.6, with state-dependent or use-dependent activity, including aryl substituted oxazoles, thiazoles, imidazoles, benzoxazoles, and benzimidazoles, which can be administered to treat therapy-resistant scenarios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiepileptic drugs are used to treat epilepsy, then seizure control is achieved in some patients, but medication-induced neurotoxicity and cognitive side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for specific sodium channel isoforms (e.g., NaV1.6, NaV1.2) rather than non-selective blockage. This selective targeting allows the drug to act on specific channel subtypes involved in seizure generation while sparing other channel types that may be critical for neuronal function, thereby reducing neurotoxicity and cognitive side effects while maintaining seizure control efficacy
Solution Approach 2:
The patent employs dynamics by developing state-dependent and use-dependent blockers that preferentially bind to sodium channels in specific states (e.g., inactive state, open state) or show enhanced blockage with repeated stimulation. This dynamic binding characteristic allows the drug to selectively inhibit hyperactive sodium channels during seizures while having minimal impact on normal neuronal firing patterns, thus reducing harmful side effects
2Reliability
If optimal doses of antiepileptic drugs are administered, then seizure control is maximized, but neurotoxicity and cognitive side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the pharmacological parameters of sodium channel blockage through structural modifications of the compound molecules. This includes adjusting binding affinity, selectivity for specific isoforms, and state-dependence characteristics. By optimizing these parameters, the drug achieves effective seizure control at lower doses with reduced neurotoxicity and cognitive impairment compared to conventional AEDs
3Adaptability or versatility
If non-selective sodium channel blockers are used, then broad spectrum seizure control is achieved, but selective targeting of pathogenic channels is lost
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for specific sodium channel isoforms (e.g., NaV1.6, NaV1.2) rather than non-selective blockage. This selective targeting allows the drug to act on specific channel subtypes involved in seizure generation while sparing other channel types that may be critical for neuronal function, thereby reducing neurotoxicity and cognitive side effects while maintaining seizure control efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit sodium channels during increased neuronal activity, reducing seizures and chronic pain with minimal neurotoxicity, offering a safer and more effective treatment option than existing AEDs.
Implementation Method 1
Compounds of the present invention are selective to certain isoforms of sodium channel, e.g., NaV1.6, and some are selective for the certain state of the NaV1.6 sodium channel, e.g., inactive state. Such properties can result in advantageous state-dependent or use-dependent activity.
Data Source
AI summary
The disclosure provides methods for treating a subject suffering from a disease associated with sodium channel activity. The method comprises administering to the subject a therapeutically effective amount of a compound according to Formula II or Formula III described in the specification, or a pharmaceutically acceptable salt, prodrug, tautomer, stereoisomer, hydrate, or solvate thereof.